Entity

Time filter

Source Type

Cambridge, United Kingdom

Cortes J.,University of Barcelona | Cortes J.,Scientia | Calvo E.,South Texas Accelerated Research Therapeutics START Madrid | Vivancos A.,University of Barcelona | And 3 more authors.
CA Cancer Journal for Clinicians | Year: 2014

Translational and clinical cancer research, as well as clinical trials and treatment of cancer, are essentially structured based on the organ in which tumors originate. However, the recent explosion of knowledge about the molecular characteristics of tumors is opening a new way to tackle cancer. This article proposes a different approach to the classification of cancer with important implications for treatment and for basic, translational, and clinical research. The authors postulate that cancers from diverse organs of origin with similar molecular traits should be managed together. The common molecular features observed in different tumors determine clinical actions in a better way than organ-based classification. Thus, comparisons between tumors residing in different locations but with shared molecular characteristics will improve the therapeutic approach and the understanding of the biology of cancer. CA Cancer J Clin 2014;64:70-74. © 2013 American Cancer Society. © 2013 American Cancer Society, Inc.


Perez E.A.,Mayo Medical School | Cortes J.,Scientia | Gonzalez-Angulo A.M.,University of Houston | Bartlett J.M.S.,Ontario Cancer Institute
Cancer Treatment Reviews | Year: 2014

Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status. © 2013 The Authors.


Patent
Scientia | Date: 2013-11-29

Provided are methods for disrupting dipolar interactions in vivo and in vitro, as wells as treating conditions associated with abnormal cell growth, by subjecting to an artificial, stable magnetic field. Also provided are assays involving an artificial, stable magnetic field. Additionally, the exposure of an artificial, stable magnetic field may be combined with other non-magnetic therapy in treatment or assays.


Helbig M.,Scientia | Helbig M.,University of Pretoria | Engelbrecht A.P.,University of Pretoria
Information Sciences | Year: 2013

When algorithms solve dynamic multi-objective optimisation problems (DMOOPs), performance measures are required to quantify the performance of the algorithm and to compare one algorithm's performance against that of other algorithms. However, for dynamic multi-objective optimisation (DMOO) there are no standard performance measures. This article provides an overview of the performance measures that have been used so far. In addition, issues with performance measures that are currently being used in the DMOO literature are highlighted. © 2013 Elsevier Inc. All rights reserved.


Patent
Scientia | Date: 2014-12-04

The disclosure provides oral solid particle formulations comprising of an iodinated imaging agent and at least one taste masking agent showing improved bioadhesive properties, and are also useful for imaging of the gastrointestinal tract.

Discover hidden collaborations